Please login to the form below

Not currently logged in

FDA to review Amgen’s cholesterol drug

US regulator accepts first in new class of PCSK9 inhibitors
Amgen flag

Amgen's investigational treatment for high cholesterol evolocumab has been accepted for review by the US FDA.

The regulator will now assess the Biologics License Application (BLA) submitted by Amgen for the monoclonal antibody, which is now on its way to be the first in a new class of medicines called PCSK9 inhibitors to reach market.

The news puts Amgen a step ahead of its rivals in what looks to be a competitive market for new cholesterol-lowering treatments as companies look to a new generation of drugs to offer an alternative to statins such as Lipitor (atorvastatin) and Crestor (rosuvastatin).

Pfizer – the developer of Lipitor – and Sanofi/Regeneron are both competing with Amgen in the PCSK9 field for hyperlipidaemia treatment.

Pfizer's bococizumab (RN316) and Sanofi/Regeneron's alirocumab (REGN727) have both reported positive results in phase III trials and the latter is expected to be filed for approval before the end of the year.

The fight has spilled out into the US courts with Amgen last month launching a lawsuit against Sanofi and Regeneron for patent infringement.

The drugs work by inhibiting the PCSK9 protein that reduces the liver's ability to remove low-density lipoprotein cholesterol – so-called 'bad' cholesterol – from the blood.

In Amgen's case the safety and effectiveness of evolocumab has been investigated in 10 phase III trials, which have been submitted to the FDA in support of the application.

Dr Sean Harper, Amgen's head of R&D, said: "Evolocumab has the potential to provide significant additional benefit when added to existing LDL cholesterol-lowering medications for patients with high cholesterol."

The FDA has set an action date of August 27 for a decision on the use of evolocumab in the US. Amgen has also submitted the drug for use in Europe.

Article by
Thomas Meek

11th November 2014

From: Sales, Regulatory



Subscribe to our email news alerts


Add my company
The Good Ideas Group

Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...

Latest intelligence

The 17th World Congress on Controversies in Neurology
This year, there was a focus on the rare disease neuromyelitis optica spectrum disorder that strikes suddenly and mainly impacts women...
Archetypes: Rethinking go-to-market expectations to drive commercial success
In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...
Tuberculosis – why it remains a major global public health challenge
Innovative collaboration is required to address the major public health challenges around TB and expedite drug development...